LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
December 14 2022 - 2:19AM
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of
care diagnostics company, today announced it has received $14.2M in
grants from the Bill & Melinda Gates Foundation for ongoing
development of its point of care molecular tuberculosis (TB)
testing system. Used with the LumiraDx multi-assay Platform, the
molecular TB test is being developed to provide highly accurate
results at a low price at the point of care enabling clinicians to
immediately commence appropriate treatment and patient management
to maximize health outcomes and minimize further spread of
infection.
According to the World Health Organization’s 2022 Global
Tuberculosis Report, the difference in the number of people who
were infected with TB and the number of people diagnosed with TB
widened in both 2020 and 2021 versus 2019 to over 4 million each
year. To address this crisis, a substantial new supply of molecular
TB tests is required. However, existing options are limited by
price, test run time, electricity requirements as well as a
reliance on a sputum sample type, which can be challenging to
collect from many patients.
The LumiraDx molecular TB test is designed to fill these gaps
and needs in the TB testing market and significantly increase
access to testing. With support from the foundation, the testing
system is being developed to provide testing at a lower cost and
incorporate a tongue swab sample which makes it easier for a higher
percentage of patients to be tested. In addition, the portability
of the LumiraDx Platform, which weighs only 1.1kg, and uses a
rechargeable battery, would allow the TB test to be used in
decentralized settings across low and middle-income countries where
lab access is limited. The LumiraDx Platform, is the only point of
care instrument that supports both molecular and immunoassay
technologies.
Ron Zwanziger, LumiraDx CEO commented, “The advancement of our
TB molecular test signifies an important step forward in LumiraDx’s
mission to increase access to accurate and affordable testing
worldwide as well as an important step forward in our molecular
testing technology. The support from the Gates Foundation is
critical in our development of the TB test and ensuring it reaches
communities where access to testing is most challenged. The
availability of these immediate results can be game changing.”
The LumiraDx platform is designed to run a variety of sample
types and technology with 12 tests currently available. The TB test
is the first molecular test the company has developed for the point
of care Platform. LumiraDx has already initiated testing of the TB
molecular test in pre-clinical studies in Africa.
About LumiraDxLumiraDx Limited (Nasdaq: LMDX)
is a next-generation point of care diagnostics company that is
transforming community-based healthcare. Its actively controlled
microfluidic technology provides fast, high performance and
accessible diagnostic solutions wherever the patient is for nearly
any testing scenario, creating unique testing options at the point
of need.
The company offers a broad menu of lab comparable tests on a
single portable Platform, with more than 30 assays on the market
and in the pipeline, covering infectious diseases, cardiovascular
diseases, diabetes, and coagulation disorders. The company also
supports high-complexity laboratory testing in an accessible
high-throughput format to leverage current molecular laboratory
operations.
Founded in 2014 and based in the UK, LumiraDx's diagnostic
testing solutions are being deployed globally by governments and
leading healthcare institutions across laboratories, urgent care,
physician offices, pharmacies, schools, and workplaces to help
screen, diagnose, and monitor wellness as well as disease.More
information on LumiraDx is available
at www.lumiradx.com.
Media
Contact: Colleen.McMillen@lumiradx.com
LumiraDx (NASDAQ:LMDX)
Historical Stock Chart
From May 2024 to Jun 2024
LumiraDx (NASDAQ:LMDX)
Historical Stock Chart
From Jun 2023 to Jun 2024